Filing Flows › Comparisons › BBIO vs ACAD
BridgeBio Pharma vs Acadia Pharmaceuticals: BBIO and ACAD compared
BridgeBio Pharma is the larger company: $353M of revenue in its latest quarter (Q3 2026) against $342M for Acadia Pharmaceuticals (Q3 2026). BridgeBio Pharma is growing faster (+193% against +23% a year earlier). Acadia Pharmaceuticals is more profitable, with an operating margin of 21.0% against -3.3%.
Where the money goes: BBIO and ACAD
BridgeBio Pharma (BBIO) · Q3 2026
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
Acadia Pharmaceuticals (ACAD) · Q3 2026
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.
| BridgeBio Pharma (BBIO) | Acadia Pharmaceuticals (ACAD) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $353M | $342M |
| Revenue growth, Y/Y | +193% | +23% |
| Operating margin | -3.3% | 21.0% |
| Net earnings | −$60.5M | $53.5M |
| Net margin | -17.1% | 15.6% |
| Operating cash flow | −$44.2M | $11.5M |
| Free cash flow | — | $10.3M |
| Market value | $14.6B | $3.7B |
| P/E | — | 10.3× |
| Analysts’ mean target | $106.85 | $30.68 |
Where the revenue comes from
BridgeBio Pharma
- Net product revenue: $253M (72%)
- License and services revenue: $79.3M (22%)
- Royalty revenue: $20.5M (6%)
Acadia Pharmaceuticals
- Nuplazid: $202M (59%)
- Daybue: $140M (41%)
Questions
Which is bigger, BridgeBio Pharma or Acadia Pharmaceuticals?
BridgeBio Pharma is the larger company: $353M of revenue in its latest quarter (Q3 2026) against $342M for Acadia Pharmaceuticals (Q3 2026).
Is BridgeBio Pharma or Acadia Pharmaceuticals growing faster?
BridgeBio Pharma is growing faster (+193% against +23% a year earlier).
Which is more profitable, BridgeBio Pharma or Acadia Pharmaceuticals?
Acadia Pharmaceuticals is more profitable, with an operating margin of 21.0% against -3.3%.
More: BridgeBio Pharma earnings · how BridgeBio Pharma makes money · Acadia Pharmaceuticals earnings · how Acadia Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.